Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection can cause a wide array of symptoms ranging from mild to severe or fatal forms of coronavirus disease 2019 (COVID-19). Furthermore, it has been observed that in a proportion of patients a variable range of symptoms may persist for a long time. An increasing number of studies have been focused on long COVID, but they have mainly been concentrated on previously hospitalized severe COVID-19 patients reporting symptoms up to 6-months after illness. The main aim of this study was to evaluate the prevalence of COVID-related symptoms 12-months after the onset of mild-to-moderate disease.

Sequelae in adults at 12 months after mild-to-moderate coronavirus disease 2019 (COVID-19) / Boscolo Rizzo, Paolo., Guida, F., Polesel, J., Marcuzzo, A.V., Capriotti, V., D'Alessandro, A., Zanelli, E., Marzolino, R., Lazzarin, C., Antonucci, P., Sacchet, E., Tofanelli, M., Borsetto, D., Gardenal, N., Pengo, M., Tirelli, G.. - In: INTERNATIONAL FORUM OF ALLERGY AND RHINOLOGY. - ISSN 2042-6976. - STAMPA. - 11:12(2021), pp. 1685-1688. [10.1002/alr.22832]

Sequelae in adults at 12 months after mild-to-moderate coronavirus disease 2019 (COVID-19)

Boscolo Rizzo Paolo.
Conceptualization
;
Guida F.;Marcuzzo A. V.;Capriotti V.;D'Alessandro A.;Zanelli E.;Marzolino R.;Lazzarin C.;Antonucci P.;Sacchet E.;Tofanelli M.;Tirelli G.
2021-01-01

Abstract

Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection can cause a wide array of symptoms ranging from mild to severe or fatal forms of coronavirus disease 2019 (COVID-19). Furthermore, it has been observed that in a proportion of patients a variable range of symptoms may persist for a long time. An increasing number of studies have been focused on long COVID, but they have mainly been concentrated on previously hospitalized severe COVID-19 patients reporting symptoms up to 6-months after illness. The main aim of this study was to evaluate the prevalence of COVID-related symptoms 12-months after the onset of mild-to-moderate disease.
2021
9-giu-2021
Pubblicato
File in questo prodotto:
File Dimensione Formato  
alr.22832.pdf

accesso aperto

Tipologia: Documento in Versione Editoriale
Licenza: Creative commons
Dimensione 301.82 kB
Formato Adobe PDF
301.82 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11368/2992413
Citazioni
  • ???jsp.display-item.citation.pmc??? 66
  • Scopus 79
  • ???jsp.display-item.citation.isi??? 79
social impact